Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2012; 18(9): 865-871
Published online Mar 7, 2012. doi: 10.3748/wjg.v18.i9.865
Published online Mar 7, 2012. doi: 10.3748/wjg.v18.i9.865
Antimicrobial agents | Dosage | |
In stable, non-critical patients | ||
With no ESBL-associated risk factors | Amoxicillin/clavulanate | 2.2 g every 6 h (2-h infusion time) |
Ciprofloxacin | 400 mg every 8 h (30-min infusion time) | |
+ | ||
Metronidazole | 500 mg every 6 h (1-h infusion time) | |
With ESBL-associated risk factors | Ertapenem | 1 g every 24 h (2-h infusion time) |
Tigecycline | 100 mg LD then 50 mg every 12 h (2-h infusion time) | |
In critically ill patients presenting | ||
With no ESBL-associated risk factors | Piperacillin/tazobactam | 9 g LD then 18 g per day via continuous infusion or 4.5 g every 6 h (4-h infusion time) |
With ESBL-associated risk factors | Meropenem | 500 mg every 6 h (6-h infusion time) |
or | ||
Imipenem | 500 mg every 4 h (3-h infusion time) | |
+ | ||
Fluconazole | 600 mg LD then 400 mg every 24 h (2-h infusion time) |
Antimicrobial agents | Dosage | |
In stable, non-critical patients | ||
With no ESBL-associated risk factors | Amoxicillin/clavulanate | 2.2 g every 6 h (2-h infusion time) |
Ciprofloxacin | 400 mg every 8 h (30-min infusion time) | |
+ | ||
Metronidazole | 500 mg every 6 h (1-h infusion time) | |
With ESBL-associated risk factors | Tigecycline | 100 mg LD then 50 mg every 12 h (2-h infusion time) |
In critically ill patients | ||
With no ESBL-associated risk factors | Piperacillin/tazobactam | 9 g LD then 18 g per day via continuous infusion or 4.5 g every 6 h (4-h infusion time) |
With ESBL-associated risk factors | Piperacillin | 8 g LD then 16 g/d via continuous infusion or 4 every 6 h (4-h infusion time) |
+ | ||
Tigecycline | 100 mg LD then 50 mg every 12 h (2-h infusion time) | |
+/- | ||
Fluconazole | 600 mg LD then 400 mg every 24 h (2-h infusion time) |
Antimicrobial agents | Dosage | |
In stable, non-critical patients | Piperacillin | 8 g LD then 16 g/d via continuous infusion or 4 every 6 h (4-h infusion time) |
+ | ||
Tigecycline | 100 mg LD then 50 mg every 12 h (2-h infusion time) | |
+ | ||
Fluconazole | 600 mg LD then 400 mg every 24 h (2-h infusion time) | |
In critically ill patients | Piperacillin | 8 g LD then 16 g/d via continuous infusion or 4 every 6 h (4-h infusion time) |
+ | ||
Tigecycline | 100 mg LD then 50 mg every 12 h (2-h infusion time) | |
+ | ||
Echinocandin | ||
Caspofungin | (loading dose of 70 mg, then 50 mg daily) | |
Anidulafungin | (loading dose of 200 mg, then 100 mg daily) | |
Micafungin | (100 mg daily) | |
Meropenem | 500 mg every 6 h (6-h infusion time) | |
or | ||
Imipenem | 500 mg every 4 h (3-h infusion time) | |
or | ||
Doripenem | 500 mg every 8 h (4-h infusion time) | |
+ | ||
Teicoplanin | 1.6 g via continuous infusion or 400 mg every 6 h (4-h infusion time) | |
+ | ||
Echinocandin | ||
Caspofungin | (loading dose of 70 mg, then 50 mg daily) | |
Anidulafungin | (loading dose of 200 mg, then 100 mg daily) | |
Micafungin | (100 mg daily) |
- Citation: Sartelli M, Catena F, Coccolini F, Pinna AD. Antimicrobial management of intra-abdominal infections: Literature's guidelines. World J Gastroenterol 2012; 18(9): 865-871
- URL: https://www.wjgnet.com/1007-9327/full/v18/i9/865.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i9.865